Analysts Are Upgrading NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) After Its Latest Results
Analysts Offer Insights on Healthcare Companies: Iovance Biotherapeutics (IOVA), GH Research (GHRS) and NewAmsterdam Pharma Company (NAMS)
Express News | NewAmsterdam Pharma Company NV : Leerink Partners Cuts Target Price to $44 From $46
Express News | Needham Maintains Buy on NewAmsterdam Pharma Co, Lowers Price Target to $40
NewAmsterdam Pharma Co Analyst Ratings
Buy Rating Affirmed for NewAmsterdam Pharma: Strategic Progress and Financial Stability Drive Confidence
TD Cowen Maintains NewAmsterdam Pharma(NAMS.US) With Buy Rating
NewAmsterdam Pharma Q1 Net Loss Narrows, Revenue Rises
10-Q: Quarterly report
NewAmsterdam Pharma 1Q Loss $39.5M >NAMS
NewAmsterdam Pharma 1Q Rev $2.98M >NAMS
NewAmsterdam Pharma 1Q >NAMS
8-K: NewAmsterdam Pharma Provides Corporate Update and Reports First Quarter Financial Results
Press Release: NewAmsterdam Pharma Provides Corporate Update and Reports First Quarter Financial Results
William Blair Maintains NewAmsterdam Pharma(NAMS.US) With Buy Rating
NewAmsterdam Pharma Presents Promising Phase 3 Trial Data
NewAmsterdam Pharma Announces Late-Breaking Data From BROADWAY and TANDEM Pivotal Studies Published in Leading Medical Journals and Presented at the European Atherosclerosis Society (EAS) Congress 2025
NewAmsterdam Pharma to Present New Clinical and Preclinical Data at 93rd EAS Congress
NewAmsterdam Pharma Company N.V. (NAMS): Among Billionaire Andreas Halvorsen's Stock Picks With Huge Upside Potential
12 Health Care Stocks Moving In Tuesday's After-Market Session